Cytogen Past Earnings Performance
Past criteria checks 0/6
Cytogen has been growing earnings at an average annual rate of 2.6%, while the Biotechs industry saw earnings growing at 1.6% annually. Revenues have been growing at an average rate of 62.7% per year.
Key information
2.6%
Earnings growth rate
15.4%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 62.7% |
| Return on equity | -29.1% |
| Net Margin | -446.7% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Cytogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3,554 | -15,873 | 8,724 | 3,193 |
| 31 Mar 24 | 3,269 | -14,775 | 8,052 | 3,316 |
| 31 Dec 23 | 3,184 | -15,770 | 8,171 | 3,117 |
| 30 Sep 23 | 2,838 | -16,401 | 8,448 | 3,702 |
| 30 Jun 23 | 2,184 | -16,288 | 8,305 | 3,847 |
| 31 Mar 23 | 1,375 | -20,543 | 8,666 | 3,908 |
| 31 Dec 22 | 761 | -18,771 | 7,595 | 3,198 |
| 30 Sep 22 | 289 | -17,196 | 10,385 | 2,776 |
| 30 Jun 22 | 294 | -17,589 | 9,684 | 2,548 |
| 31 Dec 21 | 348 | -10,871 | 8,519 | 3,315 |
Quality Earnings: A217330 is currently unprofitable.
Growing Profit Margin: A217330 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A217330's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A217330's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A217330 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.3%).
Return on Equity
High ROE: A217330 has a negative Return on Equity (-29.09%), as it is currently unprofitable.